JP7614842B2 - 抗原性エプスタインバーウイルスポリペプチド - Google Patents
抗原性エプスタインバーウイルスポリペプチド Download PDFInfo
- Publication number
- JP7614842B2 JP7614842B2 JP2020554517A JP2020554517A JP7614842B2 JP 7614842 B2 JP7614842 B2 JP 7614842B2 JP 2020554517 A JP2020554517 A JP 2020554517A JP 2020554517 A JP2020554517 A JP 2020554517A JP 7614842 B2 JP7614842 B2 JP 7614842B2
- Authority
- JP
- Japan
- Prior art keywords
- ferritin
- polypeptide
- seq
- amino acid
- ebv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/05—Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023145164A JP7719134B2 (ja) | 2018-04-03 | 2023-09-07 | 抗原性エプスタインバーウイルスポリペプチド |
| JP2025123756A JP2025166834A (ja) | 2018-04-03 | 2025-07-24 | 抗原性エプスタインバーウイルスポリペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652201P | 2018-04-03 | 2018-04-03 | |
| US62/652,201 | 2018-04-03 | ||
| PCT/US2019/025419 WO2019195314A2 (en) | 2018-04-03 | 2019-04-02 | Antigenic epstein barr virus polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023145164A Division JP7719134B2 (ja) | 2018-04-03 | 2023-09-07 | 抗原性エプスタインバーウイルスポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519598A JP2021519598A (ja) | 2021-08-12 |
| JP2021519598A5 JP2021519598A5 (cg-RX-API-DMAC7.html) | 2022-04-07 |
| JP7614842B2 true JP7614842B2 (ja) | 2025-01-16 |
Family
ID=66821298
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554517A Active JP7614842B2 (ja) | 2018-04-03 | 2019-04-02 | 抗原性エプスタインバーウイルスポリペプチド |
| JP2023145164A Active JP7719134B2 (ja) | 2018-04-03 | 2023-09-07 | 抗原性エプスタインバーウイルスポリペプチド |
| JP2025123756A Pending JP2025166834A (ja) | 2018-04-03 | 2025-07-24 | 抗原性エプスタインバーウイルスポリペプチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023145164A Active JP7719134B2 (ja) | 2018-04-03 | 2023-09-07 | 抗原性エプスタインバーウイルスポリペプチド |
| JP2025123756A Pending JP2025166834A (ja) | 2018-04-03 | 2025-07-24 | 抗原性エプスタインバーウイルスポリペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US11617780B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773708A2 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7614842B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112512566A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019195314A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| JP7614841B2 (ja) | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| ES3005559T3 (en) * | 2018-07-20 | 2025-03-14 | Aicuris Anti Infective Cures Ag | Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| CN111154803B (zh) * | 2020-01-10 | 2022-07-22 | 新乡医学院 | 一种重组EBV gHgL免疫原的制备方法及其应用 |
| US20230145420A1 (en) * | 2020-04-10 | 2023-05-11 | Vanderbilt University | Recombinant vaccines and methods of use thereof |
| US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
| CN113144187B (zh) * | 2021-01-28 | 2024-03-22 | 安徽智飞龙科马生物制药有限公司 | 一种含EB病毒gHgLgp42蛋白的自组装纳米颗粒及其制备方法与应用 |
| JP2024514183A (ja) * | 2021-04-13 | 2024-03-28 | モデルナティエックス インコーポレイテッド | エプスタイン-バーウイルスmRNAワクチン |
| TW202330594A (zh) | 2021-09-29 | 2023-08-01 | 美商莫德斯醫療公司 | 抗原結合多肽、抗原結合多肽複合物及其使用方法 |
| CN116143949A (zh) * | 2023-02-23 | 2023-05-23 | 中山大学 | 一种水痘-带状疱疹病毒疫苗及其制备方法 |
| WO2025186459A1 (en) * | 2024-03-08 | 2025-09-12 | Sanofi | Antigenic epstein barr virus polypeptides |
| WO2025215618A1 (en) * | 2024-04-12 | 2025-10-16 | Seqirus Inc. | Methods and reagents for treating or preventing ebv |
| WO2026117519A1 (en) * | 2024-11-27 | 2026-06-04 | Merck Sharp & Dohme Llc | Nanoemulsion adjuvant compositions for epstein barr virus vaccines |
| WO2026128536A1 (en) * | 2024-12-12 | 2026-06-18 | Merck Sharp & Dohme Llc | Liposomal adjuvant compositions for epstein barr virus vaccines |
| CN120365380B (zh) * | 2025-04-21 | 2026-05-15 | 易康生物(苏州)有限公司 | 一种嵌合设计的eb病毒抗原及其应用 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011506565A (ja) | 2007-12-21 | 2011-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| JP2012225885A (ja) | 2011-04-22 | 2012-11-15 | Nara Institute Of Science & Technology | 被検物質の電気化学的検出方法 |
| JP2014513678A (ja) | 2011-04-07 | 2014-06-05 | ネオトープ バイオサイエンシーズ リミテッド | Ic3b沈着を伴うタンパク質凝集に関する疾患を治療するための組成物及び方法 |
| WO2015054639A1 (en) | 2013-10-11 | 2015-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus vaccines |
| JP2015530369A (ja) | 2012-07-26 | 2015-10-15 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド | 多量体融合タンパク質ワクチン及び免疫療法 |
| WO2018005558A1 (en) | 2016-06-27 | 2018-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| JP2020520674A (ja) | 2017-04-19 | 2020-07-16 | インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine | ワクチン及び標的としてのプラスモジウムスポロゾイトnpdpペプチド、新規マラリアワクチン、及びそれに結合する抗体 |
| JP2021504445A (ja) | 2017-11-21 | 2021-02-15 | モデルナティーエックス, インコーポレイテッド | エプスタイン−バーウイルスワクチン |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0312164A1 (en) * | 1987-10-16 | 1989-04-19 | Merck & Co. Inc. | Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| WO2001075436A1 (en) | 2000-04-03 | 2001-10-11 | Board Of Trustees Of The Leland Stanford Junior University | A method for protein structure alignment |
| EP1311540B1 (en) | 2000-08-18 | 2007-12-19 | Research Foundation Of State University Of New York | Altered ospa of borrelia burgdorferi |
| US7097841B2 (en) | 2002-05-10 | 2006-08-29 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
| US7774185B2 (en) | 2004-09-14 | 2010-08-10 | International Business Machines Corporation | Protein structure alignment using cellular automata |
| US20070196389A1 (en) | 2005-11-18 | 2007-08-23 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| US7951770B2 (en) | 2007-06-13 | 2011-05-31 | Northwestern University | Peptides, peptidomimetics and small molecule inhibitors of the Epstein-Barr virus mediated fusion and entry process |
| US20110117131A1 (en) | 2008-04-09 | 2011-05-19 | Ning Huang | Production of OspA for Lyme Disease Control |
| US8623375B2 (en) | 2010-05-14 | 2014-01-07 | Baxter International Inc. | Chimeric OspA genes, proteins, and methods of use thereof |
| WO2012006180A1 (en) | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
| EP2608806B1 (en) | 2010-08-25 | 2017-10-25 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | An epstein-barr-virus vaccine |
| EP2515112B1 (en) | 2011-04-22 | 2015-08-12 | Sysmex Corporation | Method for electrochemically detecting analyte |
| US20140348865A1 (en) | 2011-09-12 | 2014-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. | Immunogens based on an hiv-1 v1v2 site-of-vulnerability |
| WO2013044203A2 (en) | 2011-09-23 | 2013-03-28 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES | Novel influenza hemagglutinin protein-based vaccines |
| WO2014018931A1 (en) | 2012-07-26 | 2014-01-30 | The General Hospital Corporation | Methods and compositions for treating autoimmune disease |
| EP4421177A3 (en) | 2013-03-13 | 2024-12-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| US9907844B2 (en) | 2013-12-11 | 2018-03-06 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines |
| CZ2014320A3 (cs) | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
| US10363301B2 (en) | 2014-05-27 | 2019-07-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Stabilized influenza hemagglutinin stem region trimers and uses thereof |
| BR112017014219A2 (en) | 2014-12-31 | 2018-03-06 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | multivalent nanoparticle-based vaccines |
| US9703095B2 (en) | 2015-01-05 | 2017-07-11 | Edward Pakhchyan | Light modulator for MEMS display |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| US10301377B2 (en) | 2015-02-24 | 2019-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| MX2018006785A (es) | 2015-12-04 | 2018-11-09 | Dana Farber Cancer Inst Inc | Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer. |
| CN115960263A (zh) | 2016-03-29 | 2023-04-14 | 美国政府(由卫生和人类服务部的部长所代表) | 取代修饰的融合前rsv f蛋白及其用途 |
| CN109310749B (zh) | 2016-06-07 | 2022-09-23 | 德国癌症研究中心 | Hpv l2肽免疫原性的改善 |
| KR102724939B1 (ko) | 2016-06-17 | 2024-11-01 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 선형 또는 분지형 폴리아크릴산 폴리머 아쥬반트를 포함하는 신규한 면역원성 제형 |
| CA3050914A1 (en) | 2017-01-27 | 2018-08-02 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| WO2019014569A1 (en) | 2017-07-13 | 2019-01-17 | City Of Hope | EXPRESSION SYSTEM FOR EXPRESSING GLYCOPROTEIN COMPLEXES OF HERPESVIRUS |
| US11964006B2 (en) | 2017-09-16 | 2024-04-23 | City Of Hope | Multivalent Epstein-Barr virus-like particles and uses thereof |
| WO2019161163A1 (en) | 2018-02-16 | 2019-08-22 | The Wistar Institute Of Anatomy And Biology | Epstein-barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same |
| JP7614841B2 (ja) | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| CN112584858A (zh) | 2018-04-03 | 2021-03-30 | 赛诺菲 | 抗原性ospa多肽 |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| JP2021519600A (ja) | 2018-04-03 | 2021-08-12 | サノフイSanofi | 抗原性インフルエンザ−フェリチンポリペプチド |
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| AU2021356220A1 (en) | 2020-10-08 | 2023-06-15 | Virothera Limited | Vaccine compositions |
| WO2023288090A1 (en) | 2021-07-16 | 2023-01-19 | California Institute Of Technology | Stoichiometric expression of messenger polycistrons |
-
2019
- 2019-04-02 CN CN201980035124.4A patent/CN112512566A/zh active Pending
- 2019-04-02 WO PCT/US2019/025419 patent/WO2019195314A2/en not_active Ceased
- 2019-04-02 JP JP2020554517A patent/JP7614842B2/ja active Active
- 2019-04-02 EP EP19729869.8A patent/EP3773708A2/en active Pending
-
2020
- 2020-10-01 US US17/061,146 patent/US11617780B2/en active Active
-
2022
- 2022-12-19 US US18/067,940 patent/US12121562B2/en active Active
-
2023
- 2023-06-15 US US18/335,893 patent/US12053503B2/en active Active
- 2023-09-07 JP JP2023145164A patent/JP7719134B2/ja active Active
-
2024
- 2024-09-17 US US18/887,723 patent/US20250127847A1/en active Pending
-
2025
- 2025-07-24 JP JP2025123756A patent/JP2025166834A/ja active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011506565A (ja) | 2007-12-21 | 2011-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| JP2014513678A (ja) | 2011-04-07 | 2014-06-05 | ネオトープ バイオサイエンシーズ リミテッド | Ic3b沈着を伴うタンパク質凝集に関する疾患を治療するための組成物及び方法 |
| JP2012225885A (ja) | 2011-04-22 | 2012-11-15 | Nara Institute Of Science & Technology | 被検物質の電気化学的検出方法 |
| JP2015530369A (ja) | 2012-07-26 | 2015-10-15 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド | 多量体融合タンパク質ワクチン及び免疫療法 |
| WO2015054639A1 (en) | 2013-10-11 | 2015-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus vaccines |
| WO2018005558A1 (en) | 2016-06-27 | 2018-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| JP2020520674A (ja) | 2017-04-19 | 2020-07-16 | インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine | ワクチン及び標的としてのプラスモジウムスポロゾイトnpdpペプチド、新規マラリアワクチン、及びそれに結合する抗体 |
| JP2021504445A (ja) | 2017-11-21 | 2021-02-15 | モデルナティーエックス, インコーポレイテッド | エプスタイン−バーウイルスワクチン |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023179457A (ja) | 2023-12-19 |
| JP2025166834A (ja) | 2025-11-06 |
| US20230277619A1 (en) | 2023-09-07 |
| US20240050518A1 (en) | 2024-02-15 |
| US20250127847A1 (en) | 2025-04-24 |
| US12053503B2 (en) | 2024-08-06 |
| CN112512566A (zh) | 2021-03-16 |
| WO2019195314A3 (en) | 2019-11-07 |
| WO2019195314A2 (en) | 2019-10-10 |
| US12121562B2 (en) | 2024-10-22 |
| US20210015896A1 (en) | 2021-01-21 |
| EP3773708A2 (en) | 2021-02-17 |
| JP7719134B2 (ja) | 2025-08-05 |
| JP2021519598A (ja) | 2021-08-12 |
| US11617780B2 (en) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7719134B2 (ja) | 抗原性エプスタインバーウイルスポリペプチド | |
| US11993636B2 (en) | Antigenic OspA polypeptides | |
| JP7614841B2 (ja) | 抗原性呼吸器合胞体ウイルスポリペプチド | |
| US11904009B2 (en) | Ferritin proteins | |
| JP2024041980A (ja) | 抗原性インフルエンザ-フェリチンポリペプチド | |
| JP7505788B2 (ja) | C9orf72に由来するジペプチドリピートタンパク質に対して指向化されたペプチド免疫原コンストラクト | |
| RU2807992C2 (ru) | Антигенные полипептиды на основе последовательности респираторно-синцитиального вируса | |
| RU2816208C2 (ru) | АНТИГЕННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ ПОСЛЕДОВАТЕЛЬНОСТИ OspA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220330 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230907 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231128 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240228 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240528 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240820 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240918 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241210 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241227 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7614842 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |